How analytics and other high-tech tools can reap better insights.
Technological change isn’t always apparent to the naked eye, says Darryl Davis, PhD.
Still, the head of biophysical research and analytics at Janssen knows how rapidly computing technology is changing biotechnology labs. In a pair of slides he presented at the Big Data and Analytics for Pharma Summit in Philadelphia, he demonstrated that change.
One slide represented laboratory workflows in 2008, while the other showed the present. In both, data are generated by plate readers or chromatography, among other functions, in a native data format. In 2008, that information was translated into a common data format before being moved to a data repository, and then into a server appliance, and eventually to the user interface.
The 2017 workflow ends the same, but in the center lies the difference. Rather than being converted into a common format, the native data are fed directly into analytics platforms.
“Some legacy practices are misaligned with current capabilities and technologies,” Davis says. The new analytics processes allow pharma to get more deliverables, better and faster, which they can build upon.
Davis’s team uses Labkey’s postgres database tool to define processes, which are fed into KNIME, a workflow manager that incorporates machine learning and data mining components. KNIME executes and analyzes the raw data, which is then kicked into RapidMiner for analytics processing. The data then go into Anaconda, which acts as a notebook and an accessible graphical workbench.
All these tools are widely available, and both KNIME and Rapidminer are open source. Though many laboratories have been tempted to build tools, Davis says, it isn’t always the most efficient idea. “Generally, any time we’ve tried to write code, it hasn’t turned out as good as these tools that already exist,” he adds.
Besides, he notes, focusing on bells and whistles may be fun, but deliverables are the ultimate goal. Existing tools, he believes, allow biotech laboratories to produce even more powerful, useful insights. The tools themselves will continue to improve, as well.
“The lab of the future will look much the same as today but, much like a smartphone compared to a landline, will have vastly different capabilities arising from technology that will be invisible to the consumer,” he concluded.
Hospitals continue to struggle with IV fluid shortage, with some still delaying surgeries
November 25th 2024Some health systems have developed conservation strategies, and Baxter International has resumed production at its North Carolina plant. But some facilities are still facing serious challenges.